Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398867 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL3836474 | 0.81 | NPC1 (0.41) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL17153248 | 0.80 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL2277574 | 0.77 | DHODH (0.60) | HTTLMNAMAPTMEN1MAPK1 | |
| SCHEMBL5362260 | 0.77 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL233377 | 0.72 | NPSR1 (0.53) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL17010980 | 0.71 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL4515216 | 0.71 | KMT2A (0.51) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL8263243 | 0.68 | MAPT (0.48) | SMN1; SMN2ALDH1A1HTTLMNARAB9A | |
| SCHEMBL1416831 | 0.68 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1HTTLMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | SMN1; SMN2 4043/4885ALDH1A1 3313/4885HTT 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.